Introduction
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), was initially approved by the Food and Drug Administration (FDA) in February, 2004 for the firstline treatment of mCRC based on a survival benefit seen in randomized clinical trials. [1] A number of bevacizumab-associated adverse events have been observed in randomized clinical trials, including gastrointestinal perforation, thromboembolic events, hypertension, and wound healing complications. [1] [2] [3] [4] [5] [6] The likelihood of these adverse events is thought to be increased in patients with certain preexisting conditions, including prior thrombosis, recent hemorrhage, or uncontrolled hypertension. The relative safety of bevacizumab in older patients -particularly those with preexisting medical comorbidities --is not well documented.
As mCRC is largely a disease of the elderly, the relative safety of bevacizumab in older patients is of great interest to clinicians. Safety data obtained in randomized clinical trials, however, may not be readily applicable to patients treated in real-world clinical settings. First, patients enrolled in randomized trials are generally more functional and younger than the broader population of patients with mCRC. For example, based on incidence estimates from the SEER database (2004) (2005) (2006) (2007) (2008) , the median age of colorectal cancer diagnosis is 70 years, with over 60% of diagnoses made in patients 65 years and older. [7] However, the median age for patients enrolled in the landmark phase III bevacizumab randomized trials in mCRC is approximately 60 years. [ 
1, 3-4]
Further, follow-up from randomized trials is not long enough to detect clinically significant late adverse events. In some situations, serious safety concerns may emerge many years after initial FDA approval (e.g. rofecoxib, erythropoietin-stimulating agents). Observational cohort studies and claims databases, for example, provide an opportunity to investigate adverse events associated with newer agents in less tightly controlled clinical settings. [8] Observational cohort data have suggested that arterial thromboembolic risk associated with bevacizumab may be higher in older patients. [9] [10] In a recent analysis using SEER-Medicare data (2002) (2003) (2004) (2005) (2006) (2007) , bevacizumab use was associated with a small survival benefit in older patients as well as a slightly increased risk of stroke and gastrointestinal perforation. [11] While this analysis indeed provides some data on relative safety of bevacizumab in older patients, the patterns and adverse events associated with bevacizumab use in light of common preexisting conditions in elderly patients remains unclear.
The purpose of this analysis was therefore to determine the prevalence of treatment-associated adverse events in older mCRC patients, to describe patterns of bevacizumab use in patients with preexisting conditions known to increase risk of drug-related adverse events, and to determine the incidence of and risk factors for serious adverse events (including deep vein thrombosis and pulmonary embolus (DVT/PE), stroke, myocardial infarction, gastrointestinal hemorrhage, and gastrointestinal perforation) in patients who do and do not receive bevacizumab.
Methods

Data Source
The source of data for this study was the National Cancer Institute's merged SEER-Medicare database, which links SEER data on cancer diagnoses and survival to claims for covered medical services for Medicare enrollees. [12] [13] [14] period following its approval and before the establishment of a J code. In order to avoid including non-elderly patients with incomplete claims data, patients were excluded from analysis if they were younger than age 65, carried a diagnosis of end stage renal disease, qualified for Medicare as a result of disability, lacked Medicare parts A and B in the 12 months before and after diagnosis, were ever diagnosed with another primary cancer, or did not have histologically confirmed disease. Because the Centers for Medicare and Medicaid Services (CMS) do not require submission of individual claims for services by Medicare HMOs, patients who were enrolled in a Medicare HMO in the 12 months before and after diagnosis were excluded. [13] Finally, patients for whom the diagnosis of mCRC was made by death certificate, by autopsy, or in the same month as death were excluded. Patients were followed from the time of diagnosis until death, or until the last date of available Medicare claims (December 31, 2009). Non-cancer comorbidity was determined using the Klabunde comorbidity score, based on the presence of ICD-9-CM diagnosis codes for 13 comorbidities in the 12 months prior to diagnosis. [16] [17] [18] Identification of Chemotherapy and Bevacizumab Usage Medicare claims can be used to identify chemotherapy utilization in colorectal cancer with good sensitivity. [19] First-line treatment was defined as chemotherapy receipt within 3 months of diagnosis. While it is presumed that most patients will receive first-line chemotherapy within 3 months of mCRC diagnosis, a sensitivity analysis was used to determine if increasing this window to 4 and 6 months respectively would significantly change the estimated number of firstline chemotherapy recipients. In order to capture all first-line chemotherapy receipt (in addition to bevacizumab receipt), generic chemotherapy administration, diagnostic, and procedural codes as well as J codes for specific agents (5-fluorouracil, oxaliplatin, irinotecan) were identified.
Capecitabine use was identified in the outpatient and hospital inpatient (MedPAR) files as well as the Durable Medical Equipment (DME) file. Patients were considered to have received bevacizumab only if its specific J code could be identified. If no chemotherapy claims were present within 3 months of diagnosis (either generic claims or specific J codes), then patients were considered not to have received first-line chemotherapy. Identification of subsequent 'lines' of therapy using SEER-Medicare claims is challenging, as the duration of therapy and the reasons for switching treatments (e.g. disease progression, toxicity) are not readily apparent from claims records. Nonetheless, subsequent bevacizumab use was identified for patients who did not initially receive bevacizumab as part of first-line therapy.
For all patients who received first-line chemotherapy (with or without bevacizumab), the 'backbone' chemotherapy regimen was determined based on claims for all chemotherapy drugs within the first 3 months after diagnosis. For example, if a patient had a claim for both 5-FU and oxaliplatin within 3 months of diagnosis, they were considered to have received these drugs together in combination.
Definition of Adverse Events and Preexisting Conditions:
In order to make the distinction between preexisting conditions and adverse events, an index date for each patient is defined as follows: for patients who receive chemotherapy within 3 months of diagnosis, the index date will be the date of first chemotherapy receipt. For patients who do not receive chemotherapy within 3 months of diagnosis, the index date will be the date of diagnosis.
Identification of Preexisting Conditions
Conditions known to potentially increase risk of bevacizumab-related adverse events (as described in the package insert and reported in the literature) were identified in the 12 months prior to the index date using relevant ICD-9-CM codes. [20] The conditions of interest were broadly categorized as follows: cardiovascular, cerebrovascular, gastrointestinal, tissue integrity, and pulmonary (Appendix 1).
Identification of Bevacizumab-Related Adverse Events
Adverse events were identified from the time period between index date and either death or end of follow up. There was significant overlap between preexisting conditions and adverse events (Appendix 1). Adverse events were divided into the same five categories as preexisting conditions. In order to avoid double counting a preexisting condition as an adverse event, patients who, for example, experienced a deep vein thrombosis in the 12 months prior to the index date could not be identified as experiencing this same condition as an adverse event, even if claims for this diagnosis appeared after the index date. It is impossible to determine whether claims for deep vein thrombosis after the index date would represent a new diagnosis or simply follow up claims from the previously identified preexisting condition. Nonetheless, a separate sensitivity analysis was performed to allow for 'double counting' a specific condition as both a preexisting condition and an adverse event.
To identify occurrence of hypertensive urgency/emergency, ICD-9-CM codes for hypertension and related hypertensive conditions were used, but with the additional restriction that claims must be either in the MedPAR file (indicating hospitalization) or on the same date as a claim indicating an ER visit. To ensure that hypertension was the essential cause of the hospitalization/ER visit and not a secondary condition, hypertension must have been cited as the primary diagnosis.
Data Analysis
Summary statistics were used to describe various characteristics of the study population, Adverse event incidence rates were determined for all treated patients stratified by time period of diagnosis and first-line treatment regimen (chemotherapy with or without bevacizumab).
Person-time was determined using cumulative follow-up time (from index date until end of follow up or death) for all patients. Incidence rates were reported as number of adverse events by person-time under observation (per 100,000 person-days). Incidence rates for all adverse events were determined initially. Subsequently, incidence rates for five common adverse events observed in our cohort and thought to be highly associated with bevacizumab usage (DVT/PE, stroke, myocardial infarction, gastrointestinal hemorrhage, and gastrointestinal perforation) were determined separately using the same process outlined above. Adverse event incidence rates were not determined for patients who did not receive first-line therapy.
A competing risks regression model was created to determine factors associated with first adverse event, taking into consideration death as a competing risk. The purpose of this analysis was to determine whether patients receiving first-line bevacizumab experienced a shorter time to their first treatment-related adverse event than patients receiving first-line chemotherapy without bevacizumab. As such, the primary comparison in the competing risk regression analysis was 
Results
Patient and Treatment Characteristics
A total of 6,821 patients (median age 77) were identified across both time periods (2001-2003 and 2005-2007) . Patients were well matched by age, gender, comorbidity score, and race between both diagnosis time periods (Table 1) . Similar to other SEER-Medicare mCRC analyses, approximately 62% of patients did not receive first-line chemotherapy as defined by chemotherapy claims within 3 months of diagnosis. [11, 21] In a sensitivity analysis adjusting the window of first-line chemotherapy, the majority of patients similarly did not receive chemotherapy at 4 and 6 months from diagnosis (55% and 51% respectively). of patients who did not receive first-line chemotherapy and 22% of patients who received firstline chemotherapy alone subsequently received bevacizumab at some point before death or end of follow up.
Preexisting Conditions and Adverse Events
Preexisting conditions affecting the cardiovascular (24%) and gastrointestinal (23%) systems were most common, whereas preexisting conditions affecting tissue integrity (1%) and pulmonary systems (1%) were the least common ( Table 3) . Frequencies of preexisting conditions were comparable across both diagnosis time periods.
The majority of patients (57%) experienced some type of adverse event following the index date.
Cardiovascular (36%) and gastrointestinal (29%) adverse events were most common in both time periods. Within each organ system category, a greater proportion of patients were affected by adverse events than by preexisting conditions (Table 3) . Tissue integrity adverse events were slightly more common among patients diagnosed in 2005-2007. 
Discussion
We investigated the safety of bevacizumab in older mCRC patients with various underlying comorbidities. Using SEER-Medicare claims data for mCRC patients age ≥ 65 diagnosed between 2001 and 2007, we determined the 1) prevalence of preexisting conditions which are thought to increase risk of bevacizumab-related adverse events, 2) factors associated with bevacizumab utilization, and 3) risk factors for bevacizumab-related adverse events that have been reported in the package insert and clinical trials.
Our findings suggest that, when controlling for various factors that might impact the risk of adverse events, older bevacizumab-treated patients do not experience an increased risk of adverse events (including DVT/PE, stroke, myocardial infarction, gastrointestinal hemorrhage, and gastrointestinal perforation) during the course of treatment compared with non bevacizumabtreated patients. We also did not find an increased adverse event incidence rate in patients who receive chemotherapy with bevacizumab compared with patients who receive chemotherapy alone. Importantly, we found that most preexisting conditions, with the exception of cerebrovascular conditions, were not associated with a decreased utilization of bevacizumab in older patients. While we did not observe an increased incidence of stroke in bevacizumabtreated patients, prior history of stroke or cerebrovascular hemorrhage may be a significant deterrent to bevacizumab utilization for most clinicians, as cautioned in the bevacizumab product label. It is possible that clinicians are more wary of bevacizumab use in patients with cerebrovascular conditions because these patients may be more debilitated at baseline and because cerebrovascular adverse events may be particularly morbid and difficult to manage.
Interestingly, preexisting gastrointestinal hemorrhage or perforation were both associated with a significantly increased odds of bevacizumab utilization. While bevacizumab use is contraindicated in the setting of an acute gastrointestinal perforation, both hemorrhage and perforations are common problems associated with an intact primary tumor in patients with metastatic colorectal cancer. It is possible that patients who survive these complications may be more robust and therefore better candidates for treatment. These findings suggest that oncologists' decisions to prescribe bevacizumab are influenced by some, but not all, of the precautions listed in the package insert.
Unlike a recent SEER-Medicare study which demonstrated a slightly increased risk of stroke and gastrointestinal perforation in bevacizumab recipients, we did not find such a pattern when controlling for backbone chemotherapy regimen and a variety of important preexisting conditions. Our findings suggest that in well-selected older patients, bevacizumab use is not associated with a significantly increased risk of treatment-related adverse events.
In considering these findings, several limitations should be noted. Another limitation of this analysis is that we chose to capture various preexisting conditions that might increase the risk of bevacizumab-related adverse events, but were limited by the database from determining whether presence of the specific preexisting condition increased the risk of an adverse event of the same type. For example, a claim for DVT/PE in the 12 months prior to diagnosis may appear in a particular patient's claims several years after the initial event. For the purposes of the primary analysis, we chose to take a conservative approach by not double counting preexisting conditions and adverse events of the same type in the same patient.
However, because of our inability to distinguish claims for new adverse events versus ongoing claims for a preexisting condition, we may not have been able to assess whether bevacizumab exacerbates complications related to a specific preexisting condition. We therefore conducted a sensitivity analysis to allow for double counting preexisting conditions and adverse events of the same type. In so doing, we found that patients who received chemotherapy + bevacizumab in the similar to the findings from our primary analysis. We did find, however, that patients with preexisting cardiovascular conditions had a decreased time to first adverse event (HR 1.13, 05% CI 1.02=1.25, p=0.02) compared to patients without this comorbidity. Nonetheless, we could not confirm that the adverse events experienced by these patients were de novo events. A key limitation of SEER-Medicare is therefore the inability to identify new diagnoses versus ongoing claims for previous diagnoses.
Despite these limitations, our results suggest that in a large population of older patients with mCRC treated in real-world clinical settings, patients who receive bevacizumab may not experience an increased incidence or decreased time to adverse events than patients receiving chemotherapy alone. Our findings also suggest that preexisting comorbidities do not necessarily deter oncologists from using bevacizumab in selected older patients. Few previous studies have used SEER-Medicare to explore the safety of newer biologics and chemotherapeutics in older patient populations. Particularly since older patients are not adequately represented in clinical trials, it is critical that registry and claims databases be used for safety assessments when feasible. While SEER-Medicare is an excellent source of data on older patients with cancer, similar research using other large insurance claims databases that may have more detail on the nature and timing of specific adverse events would be valuable. Understanding the major safety signals for newer agents in older patients will help to facilitate more informed risk-benefit discussions between patients and oncologists.
